leukotriene b3

LTB3 is the LTA hydrolase metabolite of LTA3 in the leukotriene biosynthetic pathway. LTB3 and LTB4 are equipotent in their pro-inflammatory effects. However, LTB3 is five times less potent than LTB4 in eliciting chemotaxis of human neutrophils.

HSD17B13-IN-11 (Compound 2), with IC50 values of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol, effectively inhibits hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound is utilized in studying various medical conditions including liver diseases, metabolic and cardiovascular disorders, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) [1].

HSD17B13-IN-12 (Compound 3), functioning as an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibits potent activity with an IC 50 value of ≤ 0.1 μM against both leukotriene B3 and estradiol. This compound is applicable in studying various conditions including liver diseases, metabolic disorders, and cardiovascular diseases like NAFLD or NASH, as well as drug-induced liver injury (DILI) [1].

HSD17B13-IN-14 (Compound 4) acts as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), achieving an IC 50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is utilized in studying various conditions, including liver diseases, metabolic disorders, and cardiovascular diseases like NAFLD or NASH, as well as drug-induced liver injury (DILI) [1].

HSD17B13-IN-15 (Compound 6) acts as an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC 50 values of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound finds applications in studying various conditions, including liver diseases, metabolic disorders, and cardiovascular diseases such as NAFLD, NASH, or drug-induced liver injury (DILI) [1].

HSD17B13-IN-16 (compound 8) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of <0.1 μM and <1 μM when using estradiol and Leukotriene B3 as substrates, respectively. The compound is notably significant in the treatment of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-17 (compound 9) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). It demonstrates inhibitory efficacy with IC50 values of ＜0.1 μM for estradiol and ＜1 μM for Leukotriene B3 as substrates. This compound is significant in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-18 (compound 13) serves as a potent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of ＜ 0.1 μM for estradiol and ＜ 1 μM for Leukotriene B3 as substrates. This compound is crucial in managing nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-19 (compound 16) acts as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values under 0.1 μM and under 1 μM when using estradiol and Leukotriene B3 as substrates, respectively. This compound is crucial in the treatment of nonalcoholic fatty liver diseases (NAFLDs), such as nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-21 (compound 17) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of < 0.1 μM for estradiol and < 1 μM for Leukotriene B3 as substrates. This compound plays a crucial role in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-23 (compound 18) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating inhibition constants (IC 50) of ＜0.1 μM and ＜1 μM when estradiol and Leukotriene B3 act as substrates, respectively. This compound is significant in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-27 (compound 30) serves as a potent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 µM and approximately less than 1 µM for estradiol and Leukotriene B3, respectively, as substrates. This compound is crucial in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-31 (compound 32) serves as a highly effective inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM and less than 1 μM when using estradiol and Leukotriene B3 as substrates, respectively. This compound is critical in managing nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].